

# Replacement Result of AGM

RNS Number : 1044G

Novacyt S.A.

19 July 2019

The following amendments have been made to the announcement released on 19 July 2019 at 7:03BST under RNS No 0930G:

Changed the words "today" to "yesterday" in the first and second paragraphs.

All other details remain unchanged. The full amended text is shown below.

Novacyt S.A.

("Novacyt" or the "Company")

Results of AGM and EGM Update

Paris, France and Camberley, UK - 19 July 2019 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT) an international specialist in clinical diagnostics, announces that all resolutions proposed at the Annual General Meeting, held yesterday, were duly passed.

The Company also met yesterday to hold its Extraordinary General Meeting (EGM). The meeting was not deemed quorate due to the required minimum number of voting rights under French company law not being present or represented at the meeting. Consequently, the Company will reconvene an EGM at a later date.

- End -

For further information, please refer to [www.novacyt.com](http://www.novacyt.com) or contact:

## Contacts

Novacyt SA

Graham Mullis, Chief Executive Officer

Anthony Dyer, Chief Financial Officer

+44 (0)1223 395472

SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)

Matthew Johnson / Jamie Spotswood (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

WG Partners (Joint Broker)

Nigel Birks / Chris Lee / Claes Spång

+44 (0) 203 705 9330

FTI Consulting (International)

Brett Pollard / Victoria Foster Mitchell/ Mary Whittow

+44 (0)20 3727 1000

[brett.pollard@fticonsulting.com](mailto:brett.pollard@fticonsulting.com)/[victoria.fostermitchell@fticonsulting.com](mailto:victoria.fostermitchell@fticonsulting.com)/ [Mary.whittow@fticonsulting.com](mailto:Mary.whittow@fticonsulting.com)

FTI Consulting (France)

Arnaud de Cheffontaines / Astrid Villette

+33 (0)147 03 69 47 / +33 (0)147 03 69 51

[arnaud.decheffontaines@fticonsulting.com](mailto:arnaud.decheffontaines@fticonsulting.com) / [astrid.villette@fticonsulting.com](mailto:astrid.villette@fticonsulting.com)

## About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high quality assays and reagents worldwide. The Group directly serves oncology, microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information please refer to the website: [www.novacyt.com](http://www.novacyt.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

END

RAGGMGMNNLKGLZG